In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price target of $3.00. The company's shares closed last Thursday at $0.64, close to its 52-week low of $0.49. According to TipRanks.com, Fein 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -24.8% and a 20.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics. Matinas BioPharma has an analyst consensus of Strong Buy, with a price target consensus of $3.00.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-matinas-biopharmas-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Matinas Biopharma Charts.
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Matinas Biopharma Charts.